An ACAT inhibitor regulates SARS-CoV-2 replication and antiviral T cell activity
N. M. Schmidt, P. A. Wing, R. Peters, R. Brown, H. Wang, L. Swadling, J. Newman, N. Thakur, K. Shionoya, S. B. Morgan, T. S. Hinks, K. Watashi, D. Bailey, S. B. Hansen, M. K. Maini, J. A. McKeating
This paper shows that ACAT inhibitors like Avasimibe reduce SARS-CoV-2 replication and enhance antiviral T cell activity in patients.
bioRxiv · Apr 12, 2022 · PreprintImmunology